Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder
AssigneeThe Ohio State University Research Foundation
InventorMatthew S. Platz
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Ohio State University Research Foundation
InventorMatthew S. Platz
Estimating the term…
Cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes and methods of producing cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes. The methods comprise transforming B lymphocytes with EBV, incubating the transformed B lymphocytes with a flavin N-oxide photosensitizer, adding a non-toxic antioxidant, and exposing the lymphocytes to an activator, such as photoradiation of an appropriate wavelength to activate the photosensitizer. Also provided are methods of using the apoptotic EBV-transformed B lymphocyte cell preparations to elicit production of EBV-specific T cells in human patients. Finally, methods of treating organ transplant patients, specifically children, comprising administering an effective amount of the apoptotic EBV-transformed B-lymphocyte cell preparation to the patient prior to transplantation are provided.
A method of producing a cell preparation comprising a plurality of apoptotic EBV-transformed lymphocytes, comprising:
An apoptotic EBV-transformed B lymphocyte, wherein the apoptotic B lymphocyte comprises a DNA-flavin N-oxide adduct.
A method of eliciting production of EBV-specific T cells in a human subject, the method comprising administering a cell preparation to said subject, wherein the cell preparation comprises a plurality of apoptotic EBV-transformed B lymphocytes, the apoptotic EBV-transformed B lymphocytes comprise a DNA-flavin N-oxide adduct.
Dependencies are inferred from the claim text.